Opinion | To Prescribe or Not to Prescribe: Lecanemab Wins FDA Accelerated Approval
Given the aducanumab (Aduhelm)/FDA investigation by Congress, the timing of the lecanemab…
Browsing Tag
Aducanumab
Study Explores Impact of FDA Approval of Aducanumab on Trial Participation
Elana Gotkine
TUESDAY, Dec. 6, 2022 (HealthDay News) -- The U.S. Food and Drug Administration decision to approve aducanumab may have negatively…
Medicare Finalizes Limits on Aducanumab Coverage
In its final decision about anti-amyloid monoclonal antibodies for Alzheimer's disease, CMS…
Aducanumab Data Finally Published, but Alzheimer’s Experts Spot Problems
The long-awaited results of the twin phase III trials for aducanumab (Aduhelm), the controversial…
Alzheimer’s Concerns High; Aducanumab Knowledge Low
Concerns about Alzheimer's disease were high, but knowledge about aducanumab (Aduhelm) was low,…
National Down Syndrome Organizations Launch Joint Effort To Change CMS Proposal…
Atlanta, GA., Bismarck, ND., Burlington, MA., Denver, CO., Hoffman Estates, IL, NY, NY, Rockport, ME, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Down Syndrome Affiliates in Action (DSAIA), GiGi’s…
Brain Inflammation Seen in Four of 10 Alzheimer’s Aducanumab Patients
Brain inflammation known as amyloid-related imaging abnormalities (ARIA) occurred in about 40%…
Let Ethics Guide Aducanumab Prescribing, AAN Says
With incomplete data to guide aducanumab (Aduhelm) prescribing, neurologists face ethical…
Update on Regulatory Review of Aducanumab in the European Union
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today an update on the ongoing review of the Marketing…
One Aducanumab Patient, Six Brain Edema Episodes
A man treated with the recently approved Alzheimer's drug aducanumab (Aduhelm) had six…